OA10695A - Composition for organ cryopreservation and treatment of viral and bacterial infections - Google Patents

Composition for organ cryopreservation and treatment of viral and bacterial infections Download PDF

Info

Publication number: OA10695A
Authority: OA; OAPI
Prior art keywords: saturated; unsaturated; composition; substance; alkyl groups
Prior art date: 1995-12-15

Application number

OA9800079A

Other languages

English (en)

Inventor

Michelle Olga Patricia Visser

Original Assignee

Cryopreservation Tech Cc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-12-15

Filing date

1998-06-12

Publication date

2002-11-27

1998-06-12 Application filed by Cryopreservation Tech Cc filed Critical Cryopreservation Tech Cc

2002-11-27 Publication of OA10695A publication Critical patent/OA10695A/en

Links

210000000056 organ Anatomy 0.000 title claims abstract description 67
239000000203 mixture Substances 0.000 title claims abstract description 55
238000011282 treatment Methods 0.000 title claims abstract description 33
230000003612 virological effect Effects 0.000 title claims abstract description 31
238000005138 cryopreservation Methods 0.000 title claims abstract description 30
208000036142 Viral infection Diseases 0.000 title claims description 9
208000035143 Bacterial infection Diseases 0.000 title description 2
208000022362 bacterial infectious disease Diseases 0.000 title description 2
125000000217 alkyl group Chemical group 0.000 claims abstract description 96
229920006395 saturated elastomer Polymers 0.000 claims abstract description 78
238000000034 method Methods 0.000 claims abstract description 49
239000000126 substance Substances 0.000 claims abstract description 44
150000001408 amides Chemical class 0.000 claims abstract description 34
125000004970 halomethyl group Chemical group 0.000 claims abstract description 26
208000015181 infectious disease Diseases 0.000 claims abstract description 25
230000000813 microbial effect Effects 0.000 claims abstract description 22
239000013543 active substance Substances 0.000 claims abstract description 9
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical group CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 192
239000002577 cryoprotective agent Substances 0.000 claims description 35
230000000959 cryoprotective effect Effects 0.000 claims description 18
239000003795 chemical substances by application Substances 0.000 claims description 17
238000001816 cooling Methods 0.000 claims description 16
239000003814 drug Substances 0.000 claims description 15
238000004519 manufacturing process Methods 0.000 claims description 15
229940124597 therapeutic agent Drugs 0.000 claims description 15
210000004369 blood Anatomy 0.000 claims description 10
239000008280 blood Substances 0.000 claims description 10
241000700605 Viruses Species 0.000 claims description 9
239000000546 pharmaceutical excipient Substances 0.000 claims description 9
230000009385 viral infection Effects 0.000 claims description 8
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 7
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 claims description 6
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
239000002552 dosage form Substances 0.000 claims description 5
238000010257 thawing Methods 0.000 claims description 5
241000282414 Homo sapiens Species 0.000 claims description 4
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 4
HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 4
229960005486 vaccine Drugs 0.000 claims description 4
206010061598 Immunodeficiency Diseases 0.000 claims description 3
208000029462 Immunodeficiency disease Diseases 0.000 claims description 3
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 3
230000007813 immunodeficiency Effects 0.000 claims description 3
239000011780 sodium chloride Substances 0.000 claims description 3
230000000699 topical effect Effects 0.000 claims description 3
-1 wherein n = 4 or 5 Chemical group 0.000 claims description 3
239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims description 2
ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 2
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims description 2
229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 2
235000019796 monopotassium phosphate Nutrition 0.000 claims description 2
SGLUPQUZNTYPDE-UHFFFAOYSA-N n-(fluoromethyl)-n-methylformamide Chemical group FCN(C)C=O SGLUPQUZNTYPDE-UHFFFAOYSA-N 0.000 claims description 2
PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims description 2
239000001103 potassium chloride Substances 0.000 claims description 2
235000011164 potassium chloride Nutrition 0.000 claims description 2
229910021653 sulphate ion Inorganic materials 0.000 claims description 2
239000000829 suppository Substances 0.000 claims description 2
230000001225 therapeutic effect Effects 0.000 claims description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
239000011575 calcium Substances 0.000 claims 1
229910052791 calcium Inorganic materials 0.000 claims 1
235000017557 sodium bicarbonate Nutrition 0.000 claims 1
229960001407 sodium bicarbonate Drugs 0.000 claims 1
229910000030 sodium bicarbonate Inorganic materials 0.000 claims 1
125000004417 unsaturated alkyl group Chemical group 0.000 claims 1
210000002216 heart Anatomy 0.000 description 44
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 30
229910052757 nitrogen Inorganic materials 0.000 description 17
239000007788 liquid Substances 0.000 description 16
241000700159 Rattus Species 0.000 description 14
238000007710 freezing Methods 0.000 description 12
230000008014 freezing Effects 0.000 description 12
210000004027 cell Anatomy 0.000 description 10
238000002474 experimental method Methods 0.000 description 9
230000010412 perfusion Effects 0.000 description 9
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
230000006870 function Effects 0.000 description 8
210000004185 liver Anatomy 0.000 description 8
210000003491 skin Anatomy 0.000 description 8
230000006378 damage Effects 0.000 description 7
DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 6
239000007933 dermal patch Substances 0.000 description 6
230000000694 effects Effects 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
MXRPNYMMDLFYDL-YFKPBYRVSA-N AMCC Chemical compound CNC(=O)SC[C@@H](C(O)=O)NC(C)=O MXRPNYMMDLFYDL-YFKPBYRVSA-N 0.000 description 5
229920000742 Cotton Polymers 0.000 description 5
230000008569 process Effects 0.000 description 5
210000001519 tissue Anatomy 0.000 description 5
ATHHXGZTWNVVOU-UHFFFAOYSA-N N-methylformamide Chemical compound CNC=O ATHHXGZTWNVVOU-UHFFFAOYSA-N 0.000 description 4
210000000709 aorta Anatomy 0.000 description 4
230000003834 intracellular effect Effects 0.000 description 4
210000004072 lung Anatomy 0.000 description 4
239000000377 silicon dioxide Substances 0.000 description 4
229960001866 silicon dioxide Drugs 0.000 description 4
235000012239 silicon dioxide Nutrition 0.000 description 4
238000003860 storage Methods 0.000 description 4
238000010521 absorption reaction Methods 0.000 description 3
210000005240 left ventricle Anatomy 0.000 description 3
238000001000 micrograph Methods 0.000 description 3
239000002904 solvent Substances 0.000 description 3
238000012360 testing method Methods 0.000 description 3
231100000419 toxicity Toxicity 0.000 description 3
230000001988 toxicity Effects 0.000 description 3
210000002700 urine Anatomy 0.000 description 3
KDISMIMTGUMORD-UHFFFAOYSA-N 1-acetylpiperidine Chemical compound CC(=O)N1CCCCC1 KDISMIMTGUMORD-UHFFFAOYSA-N 0.000 description 2
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
KOCFTADHOAAXFC-UHFFFAOYSA-N HMMF Chemical compound OCN(C)C=O KOCFTADHOAAXFC-UHFFFAOYSA-N 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
238000010009 beating Methods 0.000 description 2
230000036765 blood level Effects 0.000 description 2
239000001110 calcium chloride Substances 0.000 description 2
229910001628 calcium chloride Inorganic materials 0.000 description 2
235000011148 calcium chloride Nutrition 0.000 description 2
210000000234 capsid Anatomy 0.000 description 2
230000005779 cell damage Effects 0.000 description 2
210000000038 chest Anatomy 0.000 description 2
238000005520 cutting process Methods 0.000 description 2
230000002489 hematologic effect Effects 0.000 description 2
238000007654 immersion Methods 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
231100000037 inhalation toxicity test Toxicity 0.000 description 2
230000003908 liver function Effects 0.000 description 2
230000033001 locomotion Effects 0.000 description 2
239000000463 material Substances 0.000 description 2
238000000386 microscopy Methods 0.000 description 2
238000003752 polymerase chain reaction Methods 0.000 description 2
235000018102 proteins Nutrition 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
230000004044 response Effects 0.000 description 2
201000005404 rubella Diseases 0.000 description 2
235000002639 sodium chloride Nutrition 0.000 description 2
239000007787 solid Substances 0.000 description 2
230000003442 weekly effect Effects 0.000 description 2
238000005303 weighing Methods 0.000 description 2
ZYTKAJZTLXIXOE-RELJEZBFSA-N (2r)-2-acetamido-3-sulfanylpropanoic acid;(2s)-2-amino-5-[[(2r)-1-(carboxymethylamino)-1-oxo-3-sulfanylpropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(=O)N[C@@H](CS)C(O)=O.OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O ZYTKAJZTLXIXOE-RELJEZBFSA-N 0.000 description 1
KYWXRBNOYGGPIZ-UHFFFAOYSA-N 1-morpholin-4-ylethanone Chemical compound CC(=O)N1CCOCC1 KYWXRBNOYGGPIZ-UHFFFAOYSA-N 0.000 description 1
UMJPVWFIBILILQ-UHFFFAOYSA-N 3-methyl-2-propan-2-ylbutanamide Chemical compound CC(C)C(C(C)C)C(N)=O UMJPVWFIBILILQ-UHFFFAOYSA-N 0.000 description 1
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
108010082126 Alanine transaminase Proteins 0.000 description 1
108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
241000969130 Atthis Species 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
108010074051 C-Reactive Protein Proteins 0.000 description 1
102100032752 C-reactive protein Human genes 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
208000010496 Heart Arrest Diseases 0.000 description 1
206010061216 Infarction Diseases 0.000 description 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
201000005505 Measles Diseases 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
101100400378 Mus musculus Marveld2 gene Proteins 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
239000004809 Teflon Substances 0.000 description 1
229920006362 Teflon® Polymers 0.000 description 1
230000037374 absorbed through the skin Effects 0.000 description 1
231100000293 acute skin toxicity Toxicity 0.000 description 1
125000005234 alkyl aluminium group Chemical group 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
239000003443 antiviral agent Substances 0.000 description 1
239000000022 bacteriostatic agent Substances 0.000 description 1
102000015736 beta 2-Microglobulin Human genes 0.000 description 1
108010081355 beta 2-Microglobulin Proteins 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
230000036983 biotransformation Effects 0.000 description 1
238000004159 blood analysis Methods 0.000 description 1
238000009534 blood test Methods 0.000 description 1
230000037396 body weight Effects 0.000 description 1
238000009835 boiling Methods 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
230000005587 bubbling Effects 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
238000007675 cardiac surgery Methods 0.000 description 1
230000002612 cardiopulmonary effect Effects 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
208000037887 cell injury Diseases 0.000 description 1
230000008859 change Effects 0.000 description 1
KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
230000008602 contraction Effects 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
238000005336 cracking Methods 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000000254 damaging effect Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
238000010586 diagram Methods 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
238000001493 electron microscopy Methods 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
230000001424 embryocidal effect Effects 0.000 description 1
210000002257 embryonic structure Anatomy 0.000 description 1
210000003414 extremity Anatomy 0.000 description 1
VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 description 1
210000000245 forearm Anatomy 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
239000011521 glass Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
230000010247 heart contraction Effects 0.000 description 1
210000003709 heart valve Anatomy 0.000 description 1
210000002443 helper t lymphocyte Anatomy 0.000 description 1
238000005534 hematocrit Methods 0.000 description 1
231100000334 hepatotoxic Toxicity 0.000 description 1
230000003082 hepatotoxic effect Effects 0.000 description 1
230000002631 hypothermal effect Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
239000003317 industrial substance Substances 0.000 description 1
230000007574 infarction Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
231100000016 inhalation toxicity Toxicity 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
231100000021 irritant Toxicity 0.000 description 1
239000002085 irritant Substances 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
230000007774 longterm Effects 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
238000005259 measurement Methods 0.000 description 1
210000001370 mediastinum Anatomy 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
230000002107 myocardial effect Effects 0.000 description 1
AJFDBNQQDYLMJN-UHFFFAOYSA-N n,n-diethylacetamide Chemical compound CCN(CC)C(C)=O AJFDBNQQDYLMJN-UHFFFAOYSA-N 0.000 description 1
PDUSWJORWQPNRP-UHFFFAOYSA-N n-propan-2-ylacetamide Chemical compound CC(C)NC(C)=O PDUSWJORWQPNRP-UHFFFAOYSA-N 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
231100000822 oral exposure Toxicity 0.000 description 1
231100000418 oral toxicity Toxicity 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
230000008723 osmotic stress Effects 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
239000002798 polar solvent Substances 0.000 description 1
238000004393 prognosis Methods 0.000 description 1
QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 1
229940080818 propionamide Drugs 0.000 description 1
239000011253 protective coating Substances 0.000 description 1
238000003753 real-time PCR Methods 0.000 description 1
238000011084 recovery Methods 0.000 description 1
238000003303 reheating Methods 0.000 description 1
230000010410 reperfusion Effects 0.000 description 1
239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
238000005070 sampling Methods 0.000 description 1
229910052710 silicon Inorganic materials 0.000 description 1
239000010703 silicon Substances 0.000 description 1
230000036555 skin type Effects 0.000 description 1
VNFWTIYUKDMAOP-UHFFFAOYSA-N sphos Chemical compound COC1=CC=CC(OC)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 VNFWTIYUKDMAOP-UHFFFAOYSA-N 0.000 description 1
230000008961 swelling Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical compound FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 description 1
231100000167 toxic agent Toxicity 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
238000005353 urine analysis Methods 0.000 description 1
230000001790 virustatic effect Effects 0.000 description 1
238000004017 vitrification Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
- A01N37/18—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing the group —CO—N<, e.g. carboxylic acid amides or imides; Thio analogues thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/12—Chemical aspects of preservation
- A01N1/122—Preservation or perfusion media
- A01N1/124—Disinfecting agents, e.g. antimicrobials
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/12—Chemical aspects of preservation
- A01N1/122—Preservation or perfusion media
- A01N1/125—Freeze protecting agents, e.g. cryoprotectants or osmolarity regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Dentistry (AREA)
Environmental Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Dermatology (AREA)
Organic Chemistry (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
Agronomy & Crop Science (AREA)
Pest Control & Pesticides (AREA)
Plant Pathology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

OA9800079A 1995-12-15 1998-06-12 Composition for organ cryopreservation and treatment of viral and bacterial infections OA10695A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
ZA9510674		1995-12-15
ZA965755		1996-07-05

Publications (1)

Publication Number	Publication Date
OA10695A true OA10695A (en)	2002-11-27

Family

ID=59812115

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA9800079A OA10695A (en)	1995-12-15	1998-06-12	Composition for organ cryopreservation and treatment of viral and bacterial infections

Country Status (25)

Country	Link
US (1)	US5935597A (is)
EP (1)	EP0966196A4 (is)
JP (1)	JP2000515115A (is)
KR (1)	KR20000064396A (is)
AP (1)	AP9801258A0 (is)
AU (1)	AU724026B2 (is)
BG (1)	BG102528A (is)
BR (1)	BR9612004A (is)
CA (1)	CA2240131A1 (is)
CZ (1)	CZ182098A3 (is)
EA (1)	EA001957B1 (is)
EE (1)	EE9800176A (is)
GE (1)	GEP20012423B (is)
IL (1)	IL124733A0 (is)
IS (1)	IS4763A (is)
LV (1)	LV12172B (is)
MX (1)	MX9804826A (is)
NO (1)	NO982653L (is)
NZ (2)	NZ501172A (is)
OA (1)	OA10695A (is)
PL (1)	PL327199A1 (is)
SI (1)	SI9620126A (is)
SK (1)	SK79998A3 (is)
TR (1)	TR199801066T2 (is)
WO (1)	WO1997022248A1 (is)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA984649B (en) *	1997-06-13	1999-12-17	Cryopreservation Tech Cc	"Drug delivery devices and methods for treatment of viral and microbial infections and wasting syndromes".
KR100269312B1 (ko) *	1997-10-14	2000-10-16	윤종용	실리콘막의결정화방법및이를이용한박막트랜지스터-액정표시장치(tft-lcd)의제조방법
EE200200564A (et)	2000-03-30	2004-06-15	Bristol-Myers Squibb Company	Stavudiini sisaldavad toimeainet aeglustatult vabastavad graanulid
US20040115268A1 (en) *	2000-04-26	2004-06-17	Control Delivery Systems, Inc.	Systemic delivery of antiviral agents
CA2324631A1 (en) *	2000-10-26	2002-04-26	Virodene Pharmaceutical Holdings (Proprietary) Limited	A substance or composition for the treatment of cancer
SE522979C2 (sv) *	2002-07-03	2004-03-23	Moelnlycke Health Care Ab	Sårförband innefattande en icke-enzymatisk antioxidant
US20060222692A1 (en) *	2005-03-31	2006-10-05	Fairfield Clinical Trials Llc	Method and compositions for transdermal administration of antimicrobial medications
JP5079503B2 (ja) *	2005-06-07	2012-11-21	株式会社インバイオテックス	ラジカルスカベンジャー及び活性酸素消去剤
EP2606895A4 (en) *	2010-10-12	2014-04-02	Univ Wuhan	PLASTER FOR THE TRANSDERMAL ABSORPTION OF AN ANTIVIRUS ACTIVE SUBSTANCE AND METHOD FOR THE PRODUCTION THEREOF
US11103460B2 (en)	2017-08-07	2021-08-31	Board Of Regents, The University Of Texas System	Fabrication methods for nanodelivery systems for long term controlled delivery of active pharmaceutical ingredients

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SU1119689A1 (ru) *	1982-07-28	1984-10-23	Всесоюзный Научно-Исследовательский Институт Разведения И Генетики Сельскохозяйственных Животных	Способ обработки спермы
FR2546755B1 (fr) *	1983-06-01	1986-04-25	Galoubet Jf Pellegrin Cie Ecur	Procede pour la conservation de sperme notamment des chevaux
IE60941B1 (en) *	1986-07-10	1994-09-07	Elan Transdermal Ltd	Transdermal drug delivery device
AT391809B (de) *	1988-01-12	1990-12-10	Immuno Ag	Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutplasmaprodukten
US5534260A (en) *	1989-02-23	1996-07-09	University Of Utah	Percutaneous drug delivery system
US5217860A (en) *	1991-07-08	1993-06-08	The American National Red Cross	Method for preserving organs for transplantation by vitrification
AU663925B2 (en) *	1992-02-20	1995-10-26	Aventisub Ii Inc.	Sulfonic acid derivatives in the treatment of viral diseases

1996
- 1996-12-13 NZ NZ501172A patent/NZ501172A/xx unknown
- 1996-12-13 NZ NZ330642A patent/NZ330642A/en unknown
- 1996-12-13 IL IL12473396A patent/IL124733A0/xx unknown
- 1996-12-13 AU AU16848/97A patent/AU724026B2/en not_active Ceased
- 1996-12-13 TR TR1998/01066T patent/TR199801066T2/xx unknown
- 1996-12-13 CZ CZ981820A patent/CZ182098A3/cs unknown
- 1996-12-13 KR KR1019980704451A patent/KR20000064396A/ko not_active Withdrawn
- 1996-12-13 BR BR9612004-5A patent/BR9612004A/pt unknown
- 1996-12-13 GE GEAP19964342A patent/GEP20012423B/en unknown
- 1996-12-13 WO PCT/US1996/019697 patent/WO1997022248A1/en not_active Ceased
- 1996-12-13 PL PL96327199A patent/PL327199A1/xx unknown
- 1996-12-13 EA EA199800558A patent/EA001957B1/ru not_active IP Right Cessation
- 1996-12-13 JP JP09522896A patent/JP2000515115A/ja active Pending
- 1996-12-13 AP APAP/P/1998/001258A patent/AP9801258A0/en unknown
- 1996-12-13 CA CA002240131A patent/CA2240131A1/en not_active Abandoned
- 1996-12-13 SI SI9620126A patent/SI9620126A/sl unknown
- 1996-12-13 SK SK799-98A patent/SK79998A3/sk unknown
- 1996-12-13 EP EP96945596A patent/EP0966196A4/en not_active Withdrawn
- 1996-12-13 EE EE9800176A patent/EE9800176A/xx unknown
1997
- 1997-06-13 US US08/874,425 patent/US5935597A/en not_active Expired - Lifetime
1998
- 1998-06-03 IS IS4763A patent/IS4763A/is unknown
- 1998-06-09 NO NO982653A patent/NO982653L/no not_active Application Discontinuation
- 1998-06-09 BG BG102528A patent/BG102528A/bg unknown
- 1998-06-12 OA OA9800079A patent/OA10695A/en unknown
- 1998-06-15 MX MX9804826A patent/MX9804826A/es unknown
- 1998-07-06 LV LVP-98-135A patent/LV12172B/en unknown

Also Published As

Publication number	Publication date
EP0966196A1 (en)	1999-12-29
CA2240131A1 (en)	1997-06-26
BR9612004A (pt)	1999-12-28
MX9804826A (es)	1998-10-31
US5935597A (en)	1999-08-10
NO982653D0 (no)	1998-06-09
JP2000515115A (ja)	2000-11-14
NO982653L (no)	1998-08-17
IS4763A (is)	1998-06-03
KR20000064396A (ko)	2000-11-06
EA199800558A1 (ru)	1998-12-24
WO1997022248A1 (en)	1997-06-26
NZ330642A (en)	2000-06-23
EA001957B1 (ru)	2001-10-22
LV12172A (lv)	1998-12-20
LV12172B (en)	1999-04-20
BG102528A (bg)	1999-08-31
CZ182098A3 (cs)	1998-11-11
AU724026B2 (en)	2000-09-07
TR199801066T2 (xx)	1998-08-21
IL124733A0 (en)	1999-01-26
EE9800176A (et)	1998-12-15
PL327199A1 (en)	1998-11-23
SI9620126A (sl)	1999-10-31
AU1684897A (en)	1997-07-14
SK79998A3 (en)	1999-02-11
EP0966196A4 (en)	2002-03-27
NZ501172A (en)	2000-04-28
GEP20012423B (en)	2001-05-25
AP9801258A0 (en)	1998-06-30

Publication	Publication Date	Title
EP1182926B1 (en)	2003-12-17	Method of cryopreservation of blood vessels by vitrification
US6060233A (en)	2000-05-09	Methods for the lyophilization of platelets, platelet membranes or erythrocytes
Jacobsen et al.	1984	Effect of cooling and warming rate on glycerolized rabbit kidneys
US20080220406A1 (en)	2008-09-11	Physiologically acceptable aqueous solutions and methods for their use
Schaff et al.	1978	Effect of potassium cardioplegia on myocardial ischemia and post arrest ventricular function.
OA10695A (en)	2002-11-27	Composition for organ cryopreservation and treatment of viral and bacterial infections
WO1997022248A9 (en)	1997-10-02	Composition for organ cryopreservation and treatment of viral and bacterial infections
Balderman et al.	1983	The optimal temperature for preservation of the myocardium during global ischemia
Hachida et al.	1989	A new solution (UCLA formula) for lung preservation
EP0664953B1 (en)	1999-04-28	Lung graft preservative composition and a method for viable preservation of lung grafts
Drinkwater Jr et al.	1995	Extracellular and standard University of Wisconsin solutions provide equivalent preservation of myocardial function
JP2016520580A (ja)	2016-07-14	臓器及び組織の保存溶液の酸素含量、安定性、及び貯蔵寿命を増大させるための、ポリ（０−２−ヒドロキシエチル）デンプンを含有する製剤
RU2035138C1 (ru)	1995-05-20	Способ получения стерильных кожных трансплантатов с бактерицидными свойствами
US6040132A (en)	2000-03-21	Methods for the lyophilization of living biological materials
US6300322B1 (en)	2001-10-09	Plasma-like solution
Bando et al.	1989	Successful extended hypothermic cardiopulmonary preservation for heart-lung transplantation
Karow	1991	Organ cryopreservation
HUP0001161A2 (hu)	2000-08-28	Készítmény szervek fagyasztással történő tartósítására, valamint vírusos és bakteriális fertőzések kezelésére
Sputtek et al.	1988	Further improvement of the-cryopreservation of human red blood cells with hydroxyethyl starch
Zhu et al.	1994	Clinical use of homograft stored by vitrification
Morishita et al.	1983	Potassium-verapamil cardioplegia for myocardial protection: An experimental evaluation through preservation and transplantation
Diethelm et al.	1975	Protection of the in situ kidney during temporary renal artery occlusion
Diethelm et al.	1976	Preservation of cadaver kidneys using hypothermig, hyperosmolar, intracellular washout solution
CN1204232A (zh)	1999-01-06	用于器官的低温储藏和治疗病毒和细菌感染的组合物
Pickford et al.	1989	Lipid peroxidation after 48-hr flush preservation of single left lung isografts in rats: A comparison of hypertonic citrate±verapamil hydrochloride or desferrioxamine with isotonic saline